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Abstract
Introduction: Early detection of breast cancer (BC) with mammography may cause overdiagnosis and
overtreatment, detecting tumors which would remain undiagnosed during a lifetime. The aims of this study were:
first, to model invasive BC incidence trends in Catalonia (Spain) taking into account reproductive and screening
data; and second, to quantify the extent of BC overdiagnosis.
Methods: We modeled the incidence of invasive BC using a Poisson regression model. Explanatory variables were:
age at diagnosis and cohort characteristics (completed fertility rate, percentage of women that use mammography
at age 50, and year of birth). This model also was used to estimate the background incidence in the absence of
screening. We used a probabilistic model to estimate the expected BC incidence if women in the population used
mammography as reported in health surveys. The difference between the observed and expected cumulative
incidences provided an estimate of overdiagnosis.
Results: Incidence of invasive BC increased, especially in cohorts born from 1940 to 1955. The biggest increase was
observed in these cohorts between the ages of 50 to 65 years, where the final BC incidence rates more than
doubled the initial ones. Dissemination of mammography was significantly associated with BC incidence and
overdiagnosis. Our estimates of overdiagnosis ranged from 0.4% to 46.6%, for women born around 1935 and 1950,
respectively.
Conclusions: Our results support the existence of overdiagnosis in Catalonia attributed to mammography usage,
and the limited malignant potential of some tumors may play an important role. Women should be better
informed about this risk. Research should be oriented towards personalized screening and risk assessment tools.
Introduction
Breast cancer (BC) incidence rates in women have been
increasing steadily in the 1980 s and 1990 s in many
countries. Time trends in the incidence of breast cancer
have been influenced by different factors: changes in
reproductive patterns, the introduction of screening
mammography, obesity trends, hormone replacement
therapy (HRT), oral contraceptive use and better health
awareness [1-10]. In Europe, BC incidence increased in
all countries, with or without national screening pro-
grams [6]. In Spain, where BC incidence is lower than
the European average, incidence rates have increased
since 1973, with a more marked rise during the 1990 s
[11] in parallel with the dissemination of mammogra-
phy, both opportunistic and publicly organized screen-
ing programs. In Catalonia (Spain), the annual
percentage change between 1980 to 1984 and 1995 to
1999 was 2.2% [12] and new cases of female BC were
estimated at 4,700 in the year 2008. This quantity repre-
sents 30% of all cancer diagnoses in women.
Screening increases incidence rates in three ways [13].
First, there is an immediate rise in incidence, due to the
early diagnosis of prevalent asymptomatic cancers
[14,15]. Second, age at diagnosis decreases as a result of
the lead time introduced by screening (estimated as two
to four years) [16]. Third, screening may cause overdiag-
nosis when it detects tumors which would never have
been diagnosed during a lifetime without screening
because of the lack of progressive potential or death
from other causes [17-21].
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Estimates of overdetection of invasive cancer may be
affected by important biases. Biesheuvel et al. mentioned
1) differences in the underlying breast cancer risk
between screened and unscreened populations, 2) con-
tamination of intervention and control groups, 3)
screening in the control group after the intervention
period ends, and 4) inadequate allowance for lead-time
[22]. It seems that the older trial data tend to provide
lower estimates of overdiagnosis, whereas the more
recent observational data tend toward higher estimates.
Since no decline in interval cancer rates has been
observed [23] part of the overdiagnosis increase may be
related to an increase in the sensitivity of mammogra-
phy (both for cancers that will progress and for tumors
of limited malignant potential).
Mathematical modeling may overcome some of the
previous mentioned biases. In the US, Holford estimated
the contribution of screening to the upward trend in BC
incidence using log-linear models for age, period and
birth cohort (APC) [24]. Holford’s models also provided
background estimates of trends that might have been
expected as a result of the continuation of historical
increases in the rates. The Cancer Intervention and Sur-
veillance Modeling Network (CISNET) used the back-
ground estimates as inputs for modeling the impact of
screening and adjuvant treatments on BC mortality
trends [25,26].
The interest in assessing the impact and cost-effective-
ness of breast cancer early detection programs in Cata-
lonia (Spain) led us to work with mathematical models
developed by Lee and Zelen within the CISNET [27,28].
The aims of this study are 1) to use reproductive and
screening data to model invasive BC incidence trends
and to obtain background estimates of invasive BC inci-
dence and 2) to use the Lee and Zelen mathematical
models to quantify the extent of overdetection of inva-
sive BC related to screening.
Materials and methods
Setting
In Spain there is a National Health System (NHS),
financed primarily by taxes, which provides universal
and free health coverage, including early detection of
breast cancer. Catalonia is an autonomous region of
Spain which has approximately one sixth of the Spanish
population. The Catalan Breast Cancer Screening Pro-
gram (BCSP) started gradually, at the beginning of the
1990 s, providing biennial mammography screening
tests to women 50 to 64 years old. Since the year 2000,
women older than 64 are kept in the program until the
age of 69. Before the start of and in addition to the
BCSP, there has also been a certain degree of opportu-
nistic breast cancer screening done in the public and
private health care sectors. In the 1994 Catalan Health
Survey, when most of the screening in Catalonia was
opportunistic, rates of screening mammography were
43% in women aged 40 to 49 years and 27% in women
aged 50 to 64 years [29]. In 2004, 61.2% of the invited
women participated in the BCSP and 75.7% either parti-
cipated in the BCSP or reported that they had received
recent mammograms (non-published BCSP data).
Data
To model invasive breast cancer incidence rates in Cata-
lonia, age and period specific incidence data were
obtained from the Girona and Tarragona population-
based cancer registries in Catalonia (both provinces
representing 18.5% of the total Catalan population and
covering either urban and rural areas). The Girona and
Tarragona provinces have around 750,000 and 800,000
inhabitants, respectively. Data from Girona was provided
directly by the Girona Cancer Registry and data from
Tarragona was downloaded from the International
Agency for Research on Cancer registries (IARC) [11].
Incidence data were available for calendar years 1980 to
1989 and 1991 to 2004 for Girona and 1983 to 1997 for
Tarragona. Given that the breast cancer incidence rates
in the Girona and Tarragona registries are similar [30],
both data sources were combined. Numerators for the
incidence rates were calculated adding the number of
incident cases from both registries by age and calendar
year. Denominators were calculated adding the number
of women at mid-calendar year, in the Girona and Tar-
ragona provinces, and were obtained from official census
population data [31]. We have assumed that the esti-
mated incidence rates were representative of the breast
cancer incidence in Catalonia. Ductal carcinoma in situ
(DCIS) has not been included in the analysis.
The research protocol was approved by the institu-
tional review board and ethics committee of the Hospi-
tal Universitari de Bellvitge (Barcelona) which waived
the need for informed consent.
Breast cancer incidence models
We modeled the observed incidence of invasive BC for
Catalan women aged 25 to 84 during the time period
1980 to 2004 using an age-cohort model that incorpo-
rated cohort characteristics like intensity of mammogra-
phy utilization and fecundity rate. We did not introduce
a period effect because screening mammography was
disseminated gradually in our country. We used this
model to estimate the background incidence of BC
under the assumption of no screening. Then, using a
probabilistic model that takes into account background
incidence, competing risks, distribution of sojourn time
in preclinical state, sensitivity of mammography and the
dissemination of screening in Catalonia, we estimated
the increased age-specific incidence due to lead time
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(expected incidence). Finally, we estimated overdiag-
nosis comparing the observed and expected cumulative
incidences, by cohort of birth. In the following sections
there are the models’ details.
Observed incidence model
Observed incidence rates were fitted using an age-
cohort model where the cohort effects were split into
three components. The first component refers to the
fecundity of the cohort and was measured using the
cohorts’ completed fertility rate (CFR). CFR is the aver-
age number of births per woman up to the end of the
childbearing years [32]. There is evidence that high par-
ity is protective of breast cancer independent of ages at
first and last full term pregnancies [33]. The second
component refers to the intensity that mammography
was used for each specific cohort and was measured as
the proportion of women who were having periodic
mammograms for early detection at age 50 (PM50).
This value was obtained from a previous work of model-
ing mammography dissemination in Catalonia (see the
details in Appendix A in Additional file 1) [34]. Finally,
the third component refers to the remaining cohort
characteristics once fecundity and mammography use
have been taken into account and for which we do not
have data over time, like use of HRT, use of oral contra-
ceptives, obesity, diet or health awareness. The third
component has been included in the model as the year
of birth of the cohorts.
Our BC incidence model uses age, CFR, PM50 and
year of birth to estimate the number of BC incident
cases by age and cohort of birth. It assumes a Poisson
distribution of the incident cases and takes into
account the exposed population. We used fractional
polynomials to describe the age and cohort effects in
order to increase the exibility of conventional polyno-
mial models and avoid undesirable artifacts of high-
order curves (see Appendix B in Additional file 1 and
reference [35] for more detail). Since mammography
use (PM50) and CFR had opposite trends in most of
the studied periods, and PM50 was strongly associated
with BC incidence, we decided to include CFR in the
model as an offset with the coefficient -0.15. This value
was obtained from the literature and indicates a rela-
tive risk of BC equal to 0.85 for each child born
[1,2,36].
Goodness of fit was assessed using the deviance and
the likelihood ratio test with respect to the saturated
model. Overdispersion of the Poisson model was
assessed. Plots of residuals versus fitted values and pre-
dictors were assessed to check for lack of fit related to
the scale of predictors (data not shown). Confidence
intervals of the predicted values were obtained using the
delta method and bootstrap.
Background incidence model
BC incidence in absence of screening, by cohort of birth,
was derived from the BC observed incidence model by
considering that the proportion of women having peri-
odic mammograms at age 50 (PM50) was zero. Confi-
dence intervals for background incidence were obtained
using the delta method and bootstrap.
Expected incidence and overdiagnosis estimation
Using the probabilistic model developed by Lee and
Zelen (LZ) for the CISNET [28] we estimated expected
BC incidence if women in the population had used
mammography as they reported in health surveys, and
overdiagnosis was zero. This estimate takes into account
the lead time that results when breast cancer is diag-
nosed earlier. Then the difference between the observed
and expected incidence provided an estimate of over-
diagnosis. The steps were the following (Figure 1):
1. We considered all the scenarios that assumed a)
100% of women starting screening mammography at age
z with 40 ≤ z ≤ wmax, where wmax is the highest age
attained by each cohort and b) the periodicity of the
exams was annual or biennial. For instance, for cohort
1950, wmax was 54, then z took 15 different values.
Therefore, for this cohort 30 different scenarios were
computed (15 with annual screening and 15 with bien-
nial screening).
2. We used the LZ model to estimate the number of
breast cancer incident cases by age and cohort of birth
in each of the scenarios mentioned in step 1, assuming
that each cohort had 100,000 women at birth. See the
equations in Appendices C and D in Additional file 1
and [28,37-40] for more detail.
3. We considered the dissemination of mammography
use in Catalonia by age and birth cohort in order to
obtain the scenario that best represents the real pattern
of mammography use for each cohort. Weighting the
estimates obtained for each scenario in step two by the
pattern of mammography use, we obtained the esti-
mated number of incident cases by age and birth cohort
(see Appendix B in Additional file 1).
4. For each cohort we obtained the expected cumula-
tive incidence (per 100,000 women at birth) adding the
incident cases obtained in step three. We represent this
estimate by CI e.
5. We estimated the observed cumulative incidence by
100,000 women at birth (CI o) multiplying the observed
age-specific incidence rates by the probability of being
alive at each age, and adding up all these values.
Finally the estimates of overdiagnosis by cohort of
birth were obtained using the formula:
100×
−CIo CIe
CIe
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Appendix E in Additional file 1 shows the calculation
of overdiagnosis for the cohort born in 1950 as an illus-
trative example.
The steps taken to obtain confidence intervals of the
overdiagnosis estimates are described in Appendix E.2
in Additional file 1.
Sensitivity of the overdiagnosis estimates to changes in
relevant parameters
We obtained new estimates of overdiagnosis by modify-
ing the following parameters:
1. Mean sojourn time in pre-clinical state (a). In the
LZ model a takes values in the range of two to four
years, depending on age. We estimated overdiagnosis
when a = 1 and when a = 5 for all ages. These scenar-
ios would represent tumors growing faster or slower
than in the LZ model, respectively.
2. Mammography sensitivity (b). In the LZ model b
varies from 0.35 to 0.8, depending on age of the woman
and year when mammography was performed. We esti-
mated the overdiagnosis assuming b = 0.9 for all ages.
3. Repeat mammography behavior. Since the distribu-
tions of periodicity of mammograms in Catalonia were
quite stable along different ages and calendar years, we
obtained new estimates of overdiagnosis in the most
extreme situations:
a. 1994 Health Survey for the age-group 40 to 49 years
(annual = 0.76, biennial = 0.21, irregular = 0.04).
b. 2006 Health Survey for ages from 60 to 69 years
(annual = 0.52, biennial = 0.35, irregular = 0.13).
Software
The Stata SE/10 statistical package was used to fit the
Poisson model for BC incidence, to bootstrap the resi-
duals and to obtain confidence intervals [41]. The Grid
Mathematica v6 program was used to apply the stochas-
tic LZ model, to estimate the number of BC incident
cases under different screening scenarios, and to esti-
mate overdiagnosis [42].
Results
Figure 2 shows the trend over time of the completed
fertility rate (CFR) (2a) and of the proportion of women
receiving periodic mammograms at age 50 (PM50) (2b),
two of the cohort variables used to model BC incidence.
Figure 1 Steps for estimating overdiagnosis for cohort 1950. See Appendix E.1 in Additional file 1 for a detailed description.
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Figure 2a shows that CFR decreased for women born
between 1900 and 1920 and then increased from 1920
to 1940, reaching a maximum of 2.35 children for
women born in 1940. After, the CFR decreased again.
Figure 2b shows a big increase in mammography usage
from 1935 to 1955. For a woman born after 1955 the
values of PM50 stabilized at approximately 0.8. It is
important to note that for women born between 1940
and 1955 we observed both a decrease of CFR and an
increase of PM50.
Table 1 shows the equation, the estimated coefficients
and standard errors of the BC incidence model. Frac-
tional polynomials selected powers two and three for
age, lineal for year of birth and power 0.5 for PM50.
Independent variables were centered with respect their
means. The model coefficients indicate that incidence
increased with age, year of birth and exposure to peri-
odic mammography. The square root effect of PM50 on
BC incidence indicates that the impact of mammogra-
phy use in BC incidence attenuated as PM50 increased.
The effect of fecundity on BC incidence was considered
inverse and constant overtime.
The observed BC incidence rates and the estimation
provided by the model can be observed in Figure 3
grouped by year of birth. There was agreement between
observed and predicted values. Data shows an increase
in BC incidence, especially in cohorts born from 1940 to
1955. The biggest increase of BC incidence was
observed for ages 50 to 65 years, where the lowest BC
incidence rate was less than half of the highest. The
slopes of the estimated rates for the oldest cohorts were
nearly parallel but we observed increasingly steeper
slopes for the 1935 and younger cohorts.
Figure 2 Completed fertility rate (CFR) and proportion having periodic mammograms at age 50 (PM50).
Table 1 Breast cancer incidence model; Catalonia 1980 to
2004
Coef. Std. error P-value
Age1 -38.8418 1.0854 < 0.001
Age2 0.0005 0.0002 0.002
PM501 0.6250 0.9878 < 0.001
YB1 0.0111 0.0026 < 0.001
Constant -6.0626 0.0156 < 0.001
The dependent variable is the number of observed incidence cases. The
model has an offset, which is a term with coefficient constrained to 1. offset =
log(exposed) 0.15 CFR, Age1 = (age/10)
-2 - 0.0331, Age2 = (age/10)
3 - 166.375,
PM501 = PM50
0.5 - 0.4342, YB1 = year-of-birth-1937.5. CFR: completed fertility
rate, PM50: proportion of women who were having periodic mammograms
for early detection at age 50. Deviance = 482.53. The expected number of
incident cases, E(I), can be obtained using the equation: E(I) = exp(-6.0626 -
38.8418 Age1 + 0.0005 Age2 + 0.6250PM501 + 0.0111YB1 + offset).
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Figure 4 shows the observed (dots), estimated (blue
dashed line) and background incidence rates for cohorts
1935, 1940, 1945 and 1950 (purple line). Confidence
intervals correspond to the bootstrap method and show
narrow estimations (intervals obtained by the delta
method were slightly narrower). Differences between
background and screening scenarios were insignificant
for woman born in 1935 or before (data not shown) and
increasingly higher for woman born later. This provided
the first clue to the magnitude of overdiagnosis due to
screening.
Figure 5 presents the number of incident BC cases
that would be obtained from a cohort of 100,000
women at birth in three different situations. The dashed
line indicates the number of cases under the background
incidence scenario and represents a situation of no
mammography use. The solid line indicates the number
of cases that would be diagnosed if mammography had
been used as reported in the Health Surveys. These esti-
mates were obtained by applying the LZ model to the
background incidence. The increase in incidence with
respect to the background is due to early diagnosis.
Dots represent the number of observed cases for
100,000 women at birth and have been obtained from
the observed incidence rates and probabilities of survi-
val. In the absence of overdiagnosis, the dots would
appear close to the solid line. The increasing distance
between the observed and expected values by cohort of
birth indicates that overdiagnosis has augmented over
time.
Table 2 shows the overdiagnosis estimates and confi-
dence intervals for cohorts born between 1935 and
1950. These estimates have been obtained by comparing
cumulative incidences from 40 years of age to the last
observed age in each cohort. Overdiagnosis estimates
vary from 0.4%, 95% CI (-8.8%, 12.2% ) for the 1935
cohort to 46.6%, 95% CI (22.7%, 85.2%) for the 1950
cohort.
Table 3 shows the results obtained after performing a
sensitivity analysis for the overdiagnosis estimates. The
largest change in overdiagnosis was observed when
modifying mean sojourn time in the pre-clinical state
(a). A pattern of mammography use caused a small
change in overdiagnosis (less than a 5% change between
the two extreme scenarios). Finally, the mammography
sensitivity caused changes of around 1.5% in the over-
diagnosis estimation.
Discussion
Principal findings
Breast cancer incidence in Catalonia has increased dur-
ing the twentieth century with a more marked rise in
cohorts born from 1940 to 1950, who were 30 to 40
years old at the beginning of the 1980 s. The progressive
dissemination of mammography in Catalonia was signifi-
cantly associated with this increase, once age and other
cohort characteristics were considered. Our estimates of
overdiagnosis ranged from 0.4% for women born in
1935 to 46.6% for women born in 1950.
Comparison with other studies
Incidence trends
Botha et al. studied breast cancer incidence and
mortality trends in 16 European countries until the
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Figure 3 Observed breast cancer (BC) incidence rates per 100,000 women (points) and the fitted model (lines). Each color represents a
cohort of birth.
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mid-1990 s. Increases in incidence occurred in all
countries, with or without national screening programs
and, according to the authors, were consistent with
changes in the risk factors [6]. In the USA, Holford et
al. also found an increased trend with a peak in the
mid-1980 s, when screening began to be more aggres-
sively promoted [24].
In Spain, Pollan et al. studied the trend over time of
the age-adjusted incidence rate of invasive breast cancer.
Incidence increased steadily during the 1980 s and 1990
s and it appeared to decline in 2000 to 2004 in the
Spanish provinces were screening had achieved full cov-
erage of the target population in a short time period
[43]. In Catalonia, where dissemination of screening
took longer, the change in the age adjusted incidence
trend was not observed.
In contrast to the previous studies, our incidence
model was not only designed to assess the trend of
breast cancer incidence over time but to obtain an esti-
mate of the background incidence and overdiagnosis.
Our results show a dramatic increase of age-specific
incidence rates in cohorts born after 1940 associated to
the intensity of mammography use in our region.
Overdiagnosis estimates
Overdiagnosis or overdetection estimates range from
negligible [15,44] or low [45-48] to moderate [22,49-51]
and high (50% or more) [14,52-55]. Some of the studies
did not account for lead time bias or for decreases in
incidence in older age groups no longer screened
[44,46].
A review of the eight randomized trials of mammogra-
phy found that in recent trials in which the control
group was not offered screening, an excess incidence of
breast cancer remained after many years of follow-up.
In those trials in which the control arm was offered
screening, there was no evidence of overdiagnosis,
although there was a possible shift from invasive to in
situ disease [56].
Two systematic reviews intended to shed light on
overdiagnosis of breast cancer. One of them, performed
by Biesheuvel et al. concluded that the most reliable
overdetection estimates ranged from -4% to 21% and
increased with age [22]. The other systematic review,
based on published trends in incidence of breast cancer
before and after the introduction of mammography
screening [53], included five national screening
Figure 4 Breast cancer (BC) incidence model for screening and background scenarios. Each plot shows the results for cohorts born in 1935,
1940, 1945 and 1950: observed BC incident rates per 100,000 women (points), model with (dashed blue line) and without (purple line) screening.
Confidence intervals were obtained using bootstrap.
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programs and estimated overdiagnosis in a 35% for inva-
sive cancers.
Two recent observational studies estimated overdiag-
nosis using population data. Puliti et al. [57] evaluated
the degree of overdiagnosis of breast cancer 15 years
after the introduction of service screening in Florence
(Italy). For women aged 60 to 69 years at the start of
the screening, the group that had a sufficient follow-up
period after the last screening, the authors did not find
overdiagnosis. In contrast, Morrell et al. [58], in New
South Walles (Australia) reported overdiagnosis esti-
mates of 30% and 42% (depending on the method used)
for women 50 to 69 years old. Although the study popu-
lations and methods used are different, our results are
consistent with both Puliti and Morrell studies. Similarly
to Puliti, we obtained no overdiagnosis for cohorts born
around 1935, which were in their 60 s when mammo-
graphy began to be widespread in Catalonia. And, con-
sistently to Morrell, we obtained estimates of
overdiagnosis higher than 40% for the younger cohorts
that had been intensively exposed to mammograms for
early detection.
Figure 5 Predicted breast cancer incidence rates per 100,000 women at birth. Each plot shows the results for cohorts born in 1935, 1940,
1945 and 1950: observed (points), background scenario (dashed gray line), and scenario that takes into account the actual dissemination of
mammography (purple line).
Table 2 Overdiagnosis estimation by year of birth in
Catalonia
Cohort Overdiagnosis (%) [95% conf. interval]
1935 0.4 -8.8 12.2
1940 23.3 9.1 43.4
1945 30.6 12.7 57.6
1950 46.6 22.7 85.2
Table 3 Sensitivity analysis for the cohort born in 1945
Screening pattern Parameter change Overdiagnosis (%)
Annual (z = 40) - 26.4
Annual (z = 40) b = 0.9 25.0
Annual (z = 40) a = 1 51.1
Annual (z = 40) a = 5 18.3
Biennial (z = 40) - 33.9
Mamo dissem 1994 for 40 to
49 years
- 33.8
Mamo dissem 2006 for 60 to
69 years
- 29.3
To test the sensitivity of the model we changed some of the parameters and
estimated overdiagnosis for woman born in 1945. The modified parameters
were mammography sensitivity (b) and mean sojourn time in pre-clinical state
(a). In the first five scenarios, 100% of the population started receiving
mammography at age 40 (z = 40). The last two scenarios take into account
the actual dissemination of mammography, and use as proportions of repeat
mammography behavior the most extreme vañues found in the different
health surveys (see Methods).
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Zahl et al., using a different approach, compared six-
year cumulative incidence of invasive breast cancer in a
screened and a control group in Norway [51]. All
women in the control group were invited to receive a 1-
time prevalence screen at the end of the observation
period. Since the cumulative incidence among controls
never reached that of the screened group (incidence rate
ratio = 1.22), the authors suggested that the natural
course of some screen-detected invasive breast cancers
may be to spontaneously regress. Similarly, Gotzsche et
al. in the update of the Cochrane systematic review of
screening for breast cancer with mammography esti-
mated that screening led to 30% overdiagnosis and over-
treatment, a figure consistent with our results [59].
Strengths and weaknesses
This study has several limitations: 1) Incidence data in
Catalonia was not available at the population level. The
two Catalan population based cancer registries, at the
Girona and Tarragona provinces, cover an area of
around 20% of the Catalan population. We have
assumed that the incidence of breast cancer from these
registries, was generalizable to the Catalan incidence.
We think that this assumption is acceptable because
even the cancer registries are geographically distant
within Catalonia, the incidence estimates were close.
Besides, both cancer registries report to the Interna-
tional Agency for Research on Cancer and comply with
its quality control procedures. 2) Incidence estimates
were available for a 25-year period, therefore some age-
specific incidence rates were not available. Although the
incidence model estimates were stable and precise, the
estimates of overdiagnosis for some cohorts had wide
confidence intervals. 3) We did not have information on
trends over time of important risk factors like HRT, oral
contraceptives, alcohol consumption obesity and seden-
tarism. We know that the use of HRT has been low in
Spain. During the 1990 s, the prevalence of HRT use
among Spanish women aged 45 to 64 increased progres-
sively reaching a value of 5.9% in 1998 and declined to
4.2% in 2006 [60,61]. Within a cohort of participants in
a population-based breast cancer screening program in
the city of Barcelona, the prevalence HRT peaked in
2002 at 11% in 50- to 54-year-olds and at 10.1% in 55-
to 59-year-olds, followed by a sudden reversal and a
progressive decrease [62]. Prevalence of overweight and
obesity in Spain has increased as in the majority of
other developed countries. A study of primary care
users in the Girona province showed that the proportion
of women with obesity (BMI < 30 kg/m2), in the 35 to
44 age group, increased from 6.9% in 1986 to 1989 to
12.9% in 1995 to 1999 [63]. The scarcity of information
on risk factors other than fecundity and mammography
use led us to include the year of birth in the model to
represent the remaining cohort effect. 4) Our breast
cancer incidence model used grouped data to estimate
the association between incidence rates and characteris-
tics of the exposed population at different periods of
time. Grouped data analysis may be affected by the eco-
logical fallacy or failure of aggregate level associations to
properly reflect individual level associations. We
intended to overcome this problem forcing the com-
pleted fertility rate variable to be inversely associated
with breast cancer incidence as reported in the litera-
ture. In addition, we included the effect of year of birth
in the incidence model as linear consistent with an
extended increasing trend over time. This assumption
provided a more conservative estimate of overdiagnosis
than when we fitted a higher degree polynomial func-
tion. 5) The estimates of mean sojourn time in a precli-
nical state that we have used are based on data from the
early detection randomized clinical trials [64] which did
not take overdiagnosis into account. That would have
caused mean sojourn time to appear longer than it was
[54]. If mean sojourn time in a preclinical state was
smaller than the values we used, our estimates of over-
diagnosis would be conservative (see Table 3 where our
sensitivity analysis shows the effect of changes in mean
sojourn time).
The principal strength of our study is the use of prob-
abilistic models to obtain the expected incidence of
breast cancer. Based on the background incidence and
the dissemination and patterns of use of mammography
in Catalonia we have estimated the increased age-speci-
fic incidence due to lead time. Our study does not com-
pare a screened group with a control group, it compares
the observed incidence rates with the expected ones
assuming that screening detects earlier invasive tumors
that would become apparent later during the womens’
life.
In comparison with the conventional age-period-
cohort (APC) models, our model includes two specific
cohort characteristics, the intensity of mammography
use and the completed fertility rate, which have opposite
trends during most of the study period. The agreement
between the observed and fitted incidence rates for
almost all the studied cohorts indicates the relevance of
this variables when explaining incidence changes over
time and the difficulties in interpreting APC models
when they include only one cohort effect that sum-
marizes divergent information.
Conclusions
Our results support the existence of overdiagnosis in
breast cancer screening by mammography in Catalonia.
Since our overdiagnosis estimates were high in cohorts
that have not reached the age of 60, where the impact
of competing risks is low, it seems that the limited
Martinez-Alonso et al. Breast Cancer Research 2010, 12:R58
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malignant potential of some tumors may play an impor-
tant role in overdiagnosis. As other authors have recom-
mended [20,21], women should be informed about the
benefits and harms of screening and research should be
oriented towards assessing individual risk and incorpor-
ating it to optimize the effectiveness of screening.
Additional material
Additional file 1: Appendix. The file contains further details of the
model for dissemination of mammography, equations for the estimation
of BC incidence, prevalence, mortality, and overdiagnosis.
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